Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 40Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 27Ovarian Neoplasms 23Neoplasms 23Lung Neoplasms 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Pancreatic Neoplasms 17Leukemia, Myeloid, Acute 16Head and Neck Neoplasms 16Lymphoma, Non-Hodgkin 15Neoplasm Metastasis 14Fallopian Tube Neoplasms 14Glioblastoma 13Esophageal Neoplasms 12Rectal Neoplasms 11Lymphoma 11Squamous Cell Carcinoma of Head and Neck 10Central Nervous System Neoplasms 10Carcinoma, Ovarian Epithelial 10Recurrence 9Melanoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 9Leukemia 9Stomach Neoplasms 8Prostatic Neoplasms 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Liver Neoplasms 7

Interventions

Paclitaxel 16Carboplatin 14Cisplatin 12Oxaliplatin 9Hyperthermic Intraperitoneal Chemotherapy 9Cytoreduction Surgical Procedures 9Fluorouracil 7Bevacizumab 7Doxorubicin 5Leucovorin 4Gemcitabine 4catumaxomab 3Docetaxel 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3nintedanib 2liposomal doxorubicin 2epothilone B 2Surgical Procedures, Operative 2Palliative Care 2Mitomycin 2Laparoscopy 2Interviews as Topic 2Drug Therapy 2Blood Specimen Collection 2veliparib 1tremelimumab 1talimogene laherparepvec 1strattice 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Peritoneal Neoplasms × Drug Therapy × Clear all
NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Genelux Corporation

Phase 1/2 Completed
46 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

NCT00318370 2015-09-09

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Morphotek

Phase 2 Completed
58 enrolled 12 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡